Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 4Unknown 3Terminated 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × Vaccination × Clear all
NCT01042366 2017-08-16

Dendritic Cells (DC) Vaccine for Metastatic Melanoma

University of Pittsburgh

Phase 2 Terminated
16 enrolled 8 charts
Dermatologic

Melanoma

NCT01216436 2015-05-25

Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

Duke University

Phase 1 Terminated
2 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡